Given the elevated expression levels of AKT3 and FGFR2 in specific subsets of PPLELC cells, which are distinct from NSCLC and NPC, these markers may serve as potential biomarkers for differentiating PPLELC from metastatic NPC and NSCLC, thereby improving clinical outcomes. The gene discussed is AKT3; the disease is non-small cell lung carcinoma.